Stroke: a new CHANCE for combination antiplatelet therapy?

Area of Science:

• Neurology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Transient ischaemic attack (TIA) and minor ischaemic stroke patients face a high risk of early recurrence.
• Current guidelines recommend antiplatelet therapy for secondary prevention.
• The optimal antiplatelet strategy remains an area of active investigation.

Discussion:

• A recent study evaluated clopidogrel plus aspirin versus aspirin monotherapy in Chinese patients with TIA or minor ischaemic stroke.
• The combination therapy demonstrated a significant reduction in the risk of early ischemic events.
• This suggests a potential benefit of dual antiplatelet therapy in specific patient cohorts.

Key Insights:

• Dual antiplatelet therapy (clopidogrel + aspirin) is more effective than aspirin alone in preventing early stroke recurrence in Chinese patients.
• The study provides valuable data on the efficacy of clopidogrel plus aspirin in a large Asian population.
• Risk reduction was observed for composite endpoints including stroke and other ischemic events.

Outlook:

• Further studies are warranted to determine if these findings are generalizable to non-Chinese populations.
• Investigating the optimal duration and specific indications for dual antiplatelet therapy in secondary stroke prevention is crucial.
• Long-term safety and cost-effectiveness data will be important for clinical implementation.